Navigation Links
GlySure CEO to Present CE Mark Trial Results at OneMedForum 2014
Date:1/7/2014

OXFORD, England, January 7, 2014 /PRNewswire/ --

GlySure reaches major milestone in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its European regulatory trial at the OneMedForum 2014 conference on January 13, 2014, in San Francisco.

OneMedForum 2014 will be the first time that the GlySure CEO Christopher Jones publicly presents the results of the multi-center CE Mark trial, which comprised 34 post surgery cardiac intensive care unit patients.

GlySure's announcement of the trial results marks the culmination of an exceptional year for the UK-based company. Since the start of 2013, GlySure has completed the development of the commercial version of its CBG monitor and sensor, secured ISO 13485 certification, completed a successful pilot trial on 24 cardiac ICU patients, recruited its European Director of Clinical Affairs, and delivered a successful European regulatory trial.

GlySure is currently compiling its CE Mark Technical File submission, which is the next step toward securing marketing approval of its CGBM technology in Europe. The company anticipates that it will make this submission in Q1.

"We are extremely pleased with the trial results demonstrating the ability to provide true continuous blood glucose monitoring on patients throughout their stay in cardiac intensive care," said GlySure CEO Christopher Jones. "We look forward to sharing these positive findings with the industry at OneMedForum in San Francisco next week."

OneMedForum 2014 will focus on areas of greatest investment opportunity in therapeutics, devices, diagnostics and health information and will also showcase the most promising microcap public companies and high growth private (pre-IPO) companies. More than 100 companies and 1,300 investors attend the annual event.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870, cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127, kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
2. PAREXEL International To Present At JP Morgan Healthcare Conference
3. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
4. Accuray to Present at JP Morgan 32nd Annual Healthcare Conference
5. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
6. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
7. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
8. Gateway Analytical to Present Latest Research at the Drug Delivery to the Lungs Conference in Edinburg, Scotland
9. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
10. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
Breaking Biology News(10 mins):